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ABSTRACT
Type II topoisomerases catalyze essential DNA trans-
actions and are proven drug targets. Drug dis-
crimination by prokaryotic and eukaryotic topoiso-
merases is vital to therapeutic utility, but is poorly un-
derstood. We developed a next-generation sequenc-
ing (NGS) approach to identify drug-resistance mu-
tations in eukaryotic topoisomerases. We show that
alterations conferring resistance to poisons of hu-
man and yeast topoisomerase II derive from a rich
mutational ‘landscape’ of amino acid substitutions
broadly distributed throughout the entire enzyme.
Both general and discriminatory drug-resistant be-
haviors are found to arise from different point mu-
tations found at the same amino acid position and
to occur far outside known drug-binding sites. Stud-
ies of selected resistant enzymes confirm the NGS
data and further show that the anti-cancer quinolone
vosaroxin acts solely as an intercalating poison, and
that the antibacterial ciprofloxacin can poison yeast
topoisomerase II. The innate drug-sensitivity of the
DNA binding and cleavage region of human and
yeast topoisomerases (particularly hTOP2) is addi-
tionally revealed to be significantly regulated by the
enzymes’ adenosine triphosphatase regions. Collec-
tively, these studies highlight the utility of using NGS-
based methods to rapidly map drug resistance land-
scapes and reveal that the nucleotide turnover ele-
ments of type II topoisomerases impact drug speci-
ficity.
INTRODUCTION
Type II DNA topoisomerases are ubiquitous cellular en-
zymes that generate transient breaks in chromosomes to
pass one double-stranded DNA segment through another
(1). The strand-passage activity of type II topoisomerases
is required for multiple essential processes, including tran-
scription, DNA replication and chromosome segregation
(2,3). The type IIA topoisomerase subclass catalyzes strand
passage by sequentially opening and closing three disso-
ciable subunit-subunit interfaces––termed ‘gates’––in an
adenosine triphosphate (ATP)-controlled manner (Figure
1) (4–7). A challenge faced by type II topoisomerases during
strand passage is a need to repetitively cleave and re-ligate
DNA while avoiding the accidental formation of persistent
genotoxic double-strand breaks (8).
Budding yeast encode one type IIA topoisomerase,
yTOP2, whereas mammals, including humans, possess two
isoforms, hTOP2 and hTOP2 (9). The two human iso-
forms appear to have partially independent functions (3,10).
Human TOP2 is expressed in proliferating cells (11,12),
where it participates in DNA replication, chromosome con-
densation and sister chromatid separation (10,13,14). By
contrast, hTOP2 is expressed throughout all cell types, in-
cluding terminally differentiated cells (15). In contrast to
the roles of hTOP2, hTOP2 has been found to act as an
activator of transcription, cleaving DNA at transcriptional
start sites (16–18); the activity of hTOP2 has also been
proposed to lead to neuronal stimulation and memory for-
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Figure 1. Type II topoisomerases undergo an ATP-dependent cycle of DNA-binding, strand capture, cleavage, strand passage and re-ligation to pass a
double-stranded DNA (in red) through another double-stranded DNA (in green). ATP (yellow circles) is converted to ADP (purple stars) in the process.
Topoisomerase poisons such as ciprofloxacin, etoposide and vosaroxin bind at the nucleolytic core’s two opposing DNA cleavage sites to block strand
passage and re-ligation. Drug structures under investigation here are shown, with the similar quinolone cores of ciprofloxacin and vosaroxin highlighted
in orange.
mation (19). The impact of DNA cleavage by human type
IIA topoisomerases must be tightly controlled, as TOP2-
induced chromosomal breakages can lead to neurological
diseases and therapy-related cancers (20,21).
Type IIA topoisomerases are clinically-validated targets
for a number of antibacterial and anticancer agents (22).
Although the overall architectures of the prokaryotic and
eukaryotic type IIA topoisomerases are similar (6,23–30),
small-molecule inhibitors exist that can selectively target
one group over another. For example, fluoroquinolones
such as ciprofloxacin are potent antibacterials that com-
prise nearly a quarter of the $10 billion US antibiotic
market (31). Fluoroquinolones act as ‘poisons,’ interca-
lating between DNA bases at the site of topoisomerase-
dependent cleavage (26–28,32) (Figure 1), inducing persis-
tent double-strand breaks that lead to DNA fragmentation
and cell death (33). Although generally considered quite
selective, some newer-generation fluoroquinolones, such as
gatifloxacin and moxifloxacin (which are used in the treat-
ment of tuberculosis) have been reported as displaying host
toxicity (34,35). In contrast, vosaroxin (formerly SNS-595
or voreloxin), is a non-fluorinated quinolone derivative that
has no reported antibacterial activity, but instead targets
eukaryotic topoisomerases (36) and has potential in can-
cer therapies. For example, phase III trials have shown sig-
nificantly improved response rates in patients with acute
myeloid leukemia (AML) when vosaroxin was combined
with cytarabine, compared to placebo and cytarabine com-
bined controls (37,38). Vosaroxin has also been shown to
have activity against models of glioblastoma and cervical
cancer (39,40).
Despite being the target of multiple drug families in clin-
ical use, current knowledge of how different compounds
discriminate between distinct topoisomerase orthologs re-
mains limited. To gain a greater understanding of the fac-
tors governing drug selectivity, we undertook a series of
mutagenesis screens, using a next-generation sequencing
(NGS) approach to identify a more comprehensive pic-
ture of topoisomerase variants capable of distinguishing be-
tween different quinolone scaffolds. The diversity of the re-
sistance mutant population isolated from this effort was
surprisingly rich, and showed that a number of mutations
which map outside of the DNA cleavage center (where type
II topoisomerase poisons are known to bind) can confer ei-
ther highly specific or broad-spectrum resistance, even to
drugs that were not included in the original selection. Bio-
chemical examination of several enzyme variants confirms
the outcomes of our mutagenesis screens and further led us
to discover that the susceptibly of human topoisomerases
to poisoning can be modulated by the ATPase elements of
the enzymes. Interestingly, ciprofloxacin is found to have
activity against yTOP2 in vitro and kills Saccharomyces
cerevisiae, suggesting that fluoroquinolones may have un-
explored utility as anti-fungal agents.
MATERIALS AND METHODS
Yeast top2ts complementation
Complementation studies were performed in yeast
strain S. cerevisiae JN394t2–4 (41). Plasmids pMJ1 (42)
and YEphTOP2-KLM (43) provided wild-type (WT)
hTOP2 and hTOP2, respectively. The vector-only con-
trol (pTRB302) was constructed by digesting pMJ1 with
HindIII and re-ligating to exclude htop2α. The yTOP2
complementation plasmid (pTRB318) was constructed
by replacing the htop2α gene in pMJ1 with a ytop2 ORF
encoding the full 1–1428 amino acids, using the MluI-SalI
restriction enzyme sites. Competent JN394t2–4 cells were
prepared as instructed (Sigma-Aldrich, YEAST-1 transfor-
mation kit), except the strain was grown at 25◦C because
growth of strains carrying the top2–4 allele is greatly re-
duced at 30◦C in liquid culture. Transformants of JN394t2–4
were selected on solid SC-URA plates, incubated at 30◦C.
The choice of media used for complementation (SC-URA
versus YPD) was found to impact the growth-inhibiting ca-
pacity of topoisomerase II poisons, with ciprofloxacin and
vosaroxin becoming significantly less toxic against hTOP2
and yTOP2 compared to etoposide when grown on SC-
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URA (Supplementary Figure S1A). For complementation
studies, triplicate overnight cultures were therefore grown
in YPD media at 30◦C, 200 rpm and adjusted to a final
OD600 of ∼1. The 10-fold serial dilutions were made and
spotted onto YPDA plates containing either no drugs,
500 M ciprofloxacin (Sigma-Aldrich) in ddH2O, 100 M
etoposide (Sigma-Aldrich) in dimethyl sulfoxide (DMSO)
or 100 M vosaroxin (Sunesis Pharmaceuticals Inc.) in
DMSO. Once the spots had dried, plates were incubated at
room temperature as the permissive temperature and 34◦C
for non-permissive temperature. Viable counts and images
were taken after three days of growth.
Additional mutants of pMJ1 and pTRB318 were gen-
erated by site-directed mutagenesis, using either the
QuikChange (Agilent) or ‘round-the-horn’ (44) technique.
All new constructs were sequenced in full prior to use in
complementation studies.
Chemical mutagenesis and mutant plasmid selection
Plasmids pMJ1 and pTRB318 were subjected to hydroxy-
lamine mutagenesis (45). Hydroxylamine solution was pre-
pared by dissolving 0.35 g of hydroxylamine hydrochloride
and 0.09 gNaOH in 5ml of ice-cold ddH2O. Tenmicrogram
of plasmid DNA was mixed with 500 l of hydroxylamine
solution and incubated at 42◦C for 18.5 h. The reaction
was then cleaned using a polymerase chain reaction (PCR)
clean-up kit (Macherey-Nagel) and the sample was eluted
in 50 l of ddH2O. Approximately 800 ng of mutagenized
DNA was used to transform freshly prepared competent
JN394t2–4. Transformed cells were initially divided in two
pools and plated on both solid SC-URA plates incubated
at room temperature and YPDA plates incubated at 34◦C.
The colony count at the non-permissive temperature was re-
duced∼30–35%, implying mutagenesis had been successful
and that the remaining 65–70% of colonies contained mu-
tant plasmids still able to complement the top2–4 growth
defect at 34◦C. Vosaroxin-resistant mutants of hTOP2 and
ciprofloxacin-resistant mutants of yTOP2 were selected by
plating transformants on YPDA supplemented with 100
M vosaroxin or 500 M ciprofloxacin, respectively, and
incubating at 34◦C for 3 days. Ciprofloxacin-resistant mu-
tants of yTOP2 were then picked back onto fresh YPDA
plates containing 500 M ciprofloxacin and onto a sec-
ond plate containing 100 M vosaroxin (together with WT
yTOP2 negative control patches), then again incubated at
34◦C for 3 days. The patches were compared after two
days to identify colonies that were ciprofloxacin-resistant,
vosaroxin-sensitive and ciprofloxacin-resistant, vosaroxin-
resistant.
For the small-scale screens, plasmids were extracted from
selected colonies using glass beads and brief boiling, as de-
scribed (46). The topoisomerase II ORFs were then ampli-
fied from the isolated plasmids by PCR and these ampli-
cons were sequenced directly, to avoid a further round of
potential mutation during passage through an Escherichia
coli host. To prevent the influence from any secondary mu-
tations on the isolated plasmid or within the original mu-
tant colony, identified mutations were then re-constructed
by site-directed mutagenesis and tested for drug sensitiv-
ity as described above. Three of seventeen mutants had a
different resistance profile to that expected from patching
(Supplementary Figure S1B and C). This suggested a low
error rate in this initial screening and patching process. For
the larger screen, multiple patching steps were performed in
order to reduce this error rate. It was initially unclear how
an opal nonsense mutation that was isolated (W653STOP),
could confer drug resistance. As both frame-shifted and
truncated variants of this construct could not complement
(Supplementary Figure S1D), we speculate that there is a
low level of enzyme produced from W653STOP sufficient
to promote cell growth, but that also results in fewer DNA
damage events.
For the large-scale screens, colonies were patched to
fit ∼100 colonies per plate. For the hTOP2 vosaroxin-
resistant screen, 380 colonies were patched from transfor-
mant plates onto YPDA containing 100 M vosaroxin.
For the yTOP2 ciprofloxacin-resistant, vosaroxin-sensitive
and ciprofloxacin-resistant, vosaroxin-resistant screens,
once colonies with the correct phenotype had been
identified, they were patched in groups of approxi-
mately 100 colonies back onto YPDA plates. There were
537 ciprofloxacin-resistant, vosaroxin-sensitive and 210
ciprofloxacin-resistant, vosaroxin-resistant isolated in this
manner. All plates were again incubated at 34◦C for 3 days.
To extract themutant plasmids, all colonies on a single plate
were scraped together and the surface was washed with a
further 3 ml of sterile ddH2O and cells were re-suspended
by vortexing. A 1.5 ml aliquot of this re-suspension was pel-
leted by centrifugation. DNAwas then extracted from these
cells as described above. The final DNAwas eluted in 120l
of ddH2O, at a concentration of between 1 and 3.5 g.l−1.
The mutant ORFs were amplified from each of these DNA
pools by PCR. Gel extracted products of the expected size
were taken forward for NGS.
Library preparation and computational analysis
Gel-extracted DNA products were fragmented to 200–
500 nt size distribution using NEBNext dsDNA Fragmen-
tase (NEB). Following end repair and A-tailing, Illumina-
compatible adapters were ligated, and libraries were am-
plified by PCR. Following library cleanup using AmpPure
beads, multiplexed libraries were sequenced in one lane
of a HiSeq2000 (Illumina) sequencing system in normal
run mode. Low quality raw Illumina reads were trimmed
or removed using the FASTX Toolkit (http://hannonlab.
cshl.edu/fastx toolkit/), and read-through into Illumina
adapters was removed with Cutadapt (http://code.google.
com/p/cutadapt/). Reads were mapped to provide ORF se-
quences of htop2α and ytop2 using Bowtie (47), allowing
only unique alignments and a maximum of 1 mismatch
per read. A python script was developed to perform addi-
tional analysis. First, only reads that contained mismatches
were extracted, corresponding to ∼10% of the ∼50 mil-
lion reads per sample. Next, extracted reads were sorted
for confidence. The ‘quality’ scores from the Illumina pro-
cess were used to decide which mismatches were real rather
than simply error during sequencing––only scores of 38 and
above were kept, which corresponded to 99.98% confidence
in base calling. At last, the remaining mismatches were ex-
tracted and converted to amino acid mutations together
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with a calculation of the number of supporting reads. Mu-
tations were ranked according to the number of supporting
reads and the cut-off was set as the top 100 mutations. This
corresponded to a cut-off of 4213 reads for the vosaroxin-
resistant mutants of hTOP2 and 2471 reads and 3870
reads for the ciprofloxacin-resistant, vosaroxin-sensitive
and ciprofloxacin-resistant, vosaroxin-resistant mutants of
yTOP2, respectively. Since the sequence library was from a
pooled PCR product, the numbers of reads obtained do not
correlate with colony numbers, but merely reveal those mu-
tations that are most highly represented in the pool and that
are therefore unlikely to be artifacts.
To map the mutations, sequence alignments were first
produced with Clustal Omega (48) and where needed,
mapped using Consurf (49). Structural figures were gener-
ated using PyMol (50).
Topoisomerase II cloning, expression and purification
PCR-amplified full-length topoisomerase genes were in-
serted by LIC, ligation-independent cloning (51), into
12UraB (Addgene #48304), a modified version of pRS426
(52). The resulting plasmids (hTOP2-12UraB, hTOP2-
12UraB and pTRB378 for yTOP2–12UraB) contained
galactose-inducible fusions with an N-terminal tobacco
etch virus (TEV) protease-cleavable hexahistidine tag.
Residues 409–1177 of yTOP2 were amplified and simi-
larly cloned into 12uraB to produce the yeast core enzyme
expression construct. Residues 431–1193 of hTOP2 and
residues 447–1206 of hTOP2 were amplified and cloned
by LIC into the pET-based vector plasmid 2BT (Addgene
#29666), generating IPTG-inducible fusions with an N-
terminal TEV protease-cleavable hexahistidine tag, which
could be expressed in E. coli. Mutant full-length con-
structs were generated by PCR amplification of the mutant
ORFs from complementation plasmids and LIC cloning
into 12UraB, followed by re-sequencing. Core enzyme mu-
tants were generated by site-directedmutagenesis of theWT
core constructs, as described above.
Overexpression of the full-length WT and mutant con-
structs, and the yeast core enzyme, was performed inS. cere-
visiae strain BCY123, grown in complete supplement mix-
ture dropout medium lacking uracil (CSM-URA), supple-
mented with 2% (vol.vol−1) lactic acid and 1.5% (vol.vol−1)
glycerol as carbon sources. Cells were grown at 30◦C, 150
rpm, to an OD600 of 0.8–1.0 and induced by the addition of
20 g.l−1 galactose. After a further 6 h growth at 30◦C, 150
rpm, cells were harvested by centrifugation (4500 × g, 15
min, 4◦C) then re-suspended in yeast buffer (250 mMNaCl,
1 mM EDTA), and frozen drop-wise in liquid nitrogen.
Frozen cells were cryogenically lysed using a Spex 6870
freezer mill, with 15 cycles of 1 min grinding followed by
1 min of cooling. The resulting powder was thawed in
A300 [20 mM Tris–HCl pH 8.5, 300 mM KCl, 20 mM im-
idazole pH 8.0, 10% (vol.vol−1) glycerol with protease in-
hibitors (1 g.ml−1 pepstatin A, 1 g.ml−1 leupeptin and
1 mM PMSF)] and clarified by centrifugation (17 000 ×
g, 20 min, 4◦C). The lysate supernatant was passed over
an A300-equilibratedHisTrapHP column (GEHealthcare)
then washed with 30 ml of A300 and 25 ml of A100 [20
mM Tris–HCl pH 8.5, 100 mM KCl, 20 mM imidazole
pH 8.0, 10% (vol.vol−1) glycerol with protease inhibitors],
and connected to an Akta Explorer FPLC (GE Health-
care). A HiTrap S HP column (GE Healthcare) was con-
nected in series and equilibrated with a further 5 ml of
A100. The columns were then washed with 25 ml B100 [20
mM Tris–HCl pH 8.5, 100 mM KCl, 200 mM imidazole
pH 8.0, 10% (vol.vol−1) glycerol with protease inhibitors]
to elute the tagged protein onto the S column and a further
15 ml of A100 to reduce imidazole levels. A gradient was
then applied, reaching 100% buffer C [20 mMTris–HCl pH
8.5, 500 mM KCl, 10% (vol.vol−1) glycerol with protease
inhibitors] over 25 min. Peak fractions were assessed by
sodium dodecyl sulphate-polyacrylamide gelelectrophore-
sis (SDS-PAGE), collected and concentrated in Amicon
100-kDa-cutoff concentrators (Millipore). TEV protease
was added to the concentrated samples and incubated at
4◦C overnight. This mixture was then passed over a second
HisTrap HP column equilibrated and washed with buffer
D [20 mM Tris–HCl pH 8.5, 500 mM KCl, 20 mM imida-
zole pH 8.0, 10% (vol.vol−1) glycerol] to remove uncleaved
product and protease. The flowthrough was collected and
concentrated, then separated by gel filtration using an S400
column (GE Healthcare) equilibrated in sizing buffer [20
mM Tris–HCl pH 7.9, 500 mM KCl, 10% (vol.vol−1) glyc-
erol]. Peak fractions were pooled and concentrated. Final
samples were combined with a one-third volume of stor-
age buffer [20 mM Tris–HCl pH 7.9, 500 mM KCl, 70%
(vol.vol−1) glycerol], quantified by NanoDrop (ThermoSci-
entific) and aliquots were snap frozen to be stored at−80◦C
prior to use.
The hTOP2 and hTOP2WTandmutant core enzymes
were overexpressed in E. coli strain Rosetta 2 pLysS (EMD
Millipore) by growing cells in 2x YT, at 37◦C and 150 rpm
until an OD600 ∼0.3. At this point, the temperature was re-
duced to 16◦C and cells were left to grow to an OD600 of
0.6–1.0. They were then induced with 0.5 mM IPTG and
left to growovernight (20 h) at 16◦C.Cells were harvested by
centrifugation (4500 × g, 20 min, 4◦C), then re-suspended
in buffer A800 [20 mMTris–HCl pH 7.9, 800 mMNaCl, 30
mM imidazole pH 8.0, 10% (vol.vol−1) glycerol with pro-
tease inhibitors] and frozen drop-wise in liquid N2. When
needed, cells were thawed on ice and lysed by four cycles of
sonication (15 s burst with 2 min rest on ice). Lysates were
clarified by centrifugation (17 000 × g, 30 min, 4◦C) and
the supernatant was passed over a HisTrapHP column (GE
Healthcare), equilibrated in A800. Samples were washed in
five column volumes of A800 and a further 10 column vol-
umes of A400 [20 mM Tris–HCl pH 7.9, 400 mMNaCl, 30
mM imidazole pH 8.0, 10% (vol.vol−1) glycerol with pro-
tease inhibitors]. Protein was then eluted with B400 [20 mM
Tris–HCl pH 7.9, 400 mM NaCl, 500 mM imidazole pH
8.0, 10% (vol.vol−1) glycerol with protease inhibitors]. The
eluted samples were concentrated in Amicon 30-kDa-cutoff
concentrators (Millipore). TEV was added and the sample
was dialysed against 1 L of A400 overnight at 4◦C. This
mixture was then passed over a second HisTrap HP column
equilibrated andwashedwith bufferA400. The flowthrough
was collected and concentrated, then separated by gel filtra-
tion using an S300 column (GE Healthcare) on a Bio-Rad
DuoFlow system, equilibrated in sizing buffer [50mMTris–
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HCl pH 7.9, 500 mM KCl, 10% (vol.vol−1) glycerol]. Peak
fractions were pooled and concentrated. Final samples were
combinedwith a one-third volume of storage buffer [20mM
Tris–HCl pH 7.9, 500 mM KCl, 70% (vol.vol−1) glycerol],
quantified by NanoDrop (ThermoScientific) and aliquots
were snap frozen to be stored at −80◦C prior to use.
Preparation of plasmid DNA substrates
Negatively supercoiled pSG483 (2927 bp), a pBlueScript
SK+ (Agilent) derivative containing an Nb.BbvCI site, was
prepared fromE. coliXL-1 blue cells (Agilent) using amax-
iprep kit (Macherey-Nagel). A portion of this sample was
treatedwith BamHI (NEB) to form linear plasmid. Another
portion of this sample was nicked with Nb.BbvCI (NEB)
and an aliquot was removed to make a nicked pSG483
stock. A further aliquot was ligated with T4 DNA ligase
(NEB), to form relaxed pSG483. All plasmid forms were
purified by phenol/chloroform extraction and ethanol pre-
cipitation prior to use.
Plasmid assays
Aliquots of full-length test protein were thawed on ice for
10min. These were then serially diluted in 2-fold steps using
protein dilution buffer [50 mMTris pH 7.5, 500 mMKOAc,
2 mM MgOAc, 1 mM dithiothreitol (DTT), 50 g.ml−1
bovine serum albumin (BSA) and 10% (vol.vol−1) glycerol],
down to 156.25 nM of topoisomerase II dimers. A reaction
master mixture was made containing four parts diluted en-
zyme, five parts 4× reaction buffer [40 mM Tris pH 7.5,
38.4 mMMgOAc, 4 mM DTT, 100 g.ml−1 BSA and 32%
(vol.vol−1) glycerol] and one part of a 500 ng.l−1 solu-
tion of substrate (either negatively supercoiled or relaxed)
pSG483 plasmid DNA. The master mixture was incubated
on ice for 5 min. Drug titrations were prepared by mixing
2 l of an appropriate drug dilution (or 2 l of solvent for
‘zero drug’ controls’) with 1 l of 20 mM ATP and 7 l
of ddH2O. These 10-l drug mixtures were then added to
10-l aliquots of the full reaction mixture on ice, quickly
transferred to 37◦C and incubated for 30 min. Final reac-
tion conditions were 60 nM full-length dimers, 15 nM su-
percoiled pSG483, variable drug content (or solvent), 1 mM
ATP, 20 mM Tris pH 7.5, 100 mMKOAc, 10 mMMgOAc,
1.2 mM DTT, 35 g.ml−1 BSA and 10% (vol.vol−1) glyc-
erol. Following incubation the reactions were first quenched
with 2 l of stopping buffer [5% (wt.vol−1) SDS and 125
mM EDTA], followed by adding 1 l of 12 mg.ml−1 pro-
teinase K and a further incubation at 37◦C for 30min. Sam-
ples were stored on ice until immediately before gel load-
ing, whereupon a 6× agarose gel loading dye was added
and the samples were warmed to 37◦C for 5 min. Samples
were separated by electrophoresis in 1.4% (wt.vol−1) TAE
agarose gels (50 mM Tris–HCl, pH 7.9, 40 mM NaOAc
and 1 mM EDTA pH 8.0 running buffer), with and with-
out ethidium bromide (0.5 g.ml−1) for 6–15 h at 2–2.5
V/cm. To visualize the DNA, gels run without ethidium
bromide were poststained with 0.5 g.ml−1 ethidium bro-
mide in TAE buffer for 30 min, destained in TAE buffer for
a further 30 min and exposed to UV illumination. Super-
coiled relaxation/cleavage assays were performed with the
core enzymes as per the supercoil relaxation assays above,
except the final concentration of core dimers used in the as-
says was 50 with 10 nM of supercoiled pSG483. All reac-
tions were ran in triplicate and gel images were analyzed us-
ing ImageJ (53), and data were plotted using Prism (Graph-
Pad Software).
Ligation assay
Reactions were constructed as for the above supercoiling as-
says, except there was no protein present, no ATP and the
DNA substrate used was 300 ng of nicked pSG483. Follow-
ing 30 min incubation at 37◦C, 1 l of 20 mM ATP was
added together with 1 l of T4 DNA ligase (NEB). These
samples were then incubated for a further 30 min at 37◦C.
Reactions were stopped, separated by gel electrophoresis
and visualized as above.
RESULTS
Drug-resistant type II topoisomerase mutations can be
broadly acting or highly selective for specific poisons
We first set out to investigate how eukaryotic type II topoi-
somerases discriminate between different poisons by per-
forming a genetic screen for drug-resistant variants. As-
says that selected for resistant variants were carried out us-
ing the S. cerevisiae strain JN394t2–4 (41), which contains a
temperature-sensitive allele for yTOP2 and is deficient in the
repair of DNAdouble strand breaks due to a deletion of the
RAD52 gene. At a non-permissive temperature for the top2–
4 allele of 34◦C, both hTOP2 and yTOP2 fully comple-
mented growth, as assessed by viable counts (42), whereas
hTOP2 provided only an intermediate level of comple-
mentation (Figure 2A). These complementation behaviors
were consistent with prior studies (43). The sensitivity of
the complemented yeast was then tested against three topoi-
somerase poisons: two quinolone derivatives, vosaroxin
and ciprofloxacin, and the anticancer epipodophyllotoxin,
etoposide (Figure 1). Ciprofloxacin had no impact on the
growth of JN394t2–4 when the cells contained hTOP2 and
hTOP2 expressing plasmids, but the drug strongly inhib-
ited the growth of cells expressing yTOP2 (Figure 2A).
Vosaroxin and etoposide disrupted cell growth regardless of
the complementing topoisomerase (Figure 2A).
Given the comparatively weak complementation behav-
ior of hTOP2, we elected to mutagenize only the hTOP2
and yTOP2 complementing plasmids for use in resistance
screens. Following hydroxylamine treatment of plasmid
DNA (54) and transformation of JN394t2–4, functional
vosaroxin-resistant (VosR) alleles of hTOP2 were selected
by growth at the non-permissive temperature onYPDplates
containing 100 Mvosaroxin. Plasmid DNAwas extracted
from a subset of VosR colonies and the hTOP2α alle-
les were sequenced to identify potential mutations. Each
identified mutation was re-introduced into the WT com-
plementing plasmid by site-directed mutagenesis, followed
by re-transformation and verification of drug sensitivity
phenotypes (Figure 2B). All mutant plasmids tested ap-
peared VosR to varying degrees. Three different single point
mutations in hTOP2 (E571K, A652T and L926F) each
caused a 100-fold increase in viable cell count when grown
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No drug Ciprofloxacin 500 μM Etoposide 100 μM Vosaroxin 100 μM
hTOP2α
hTOP2β
yTOP2
10-2 10-3 10-4 10-5 10-6 10-2 10-3 10-4 10-5 10-6 10-2 10-3 10-4 10-5 10-6 10-2 10-3 10-4 10-5 10-6
A
B
Vector control
G474A V475M
G551S (22)
E571K
I636M (88) 
A652T (7)
S654N (49)
P716H
P716T
Q726H
T858S
L926F
hTOP2α VosR
Figure 2. Screening for poison-resistant type II topoisomerases. (A) Viable counts of JN394t2–4 transformed with complementation constructs, serially
diluted as indicated and plated at non-permissive temperature (34◦C), in the absence and presence of topoisomerase poisons. Images are representative
of triplicate cultures. (B) Viable counts of JN394t2–4 complementation by hTOP2 mutants. Numbers in parentheses indicate the rank position of the
mutation if it falls within the top 100 hits from the later NGS screen.
with 100 M vosaroxin in comparison to WT hTOP2
(Figure 2A and B); the hTOP2E571K mutation has been
identified previously in a screen for m-AMSA resistance
(55). A second set of single and double hTOP2 mu-
tations (G474A/V475M, G551S, I636M, S654N, P716H,
P716T, Q726H and T858S) provided greater resistance to
vosaroxin, increasing viable cell counts 10 000-fold (Fig-
ure 2B). All mutations tested also conferred resistance to
etoposide (EtopR), despite an absence of selection against
the drug, with hTOP2E571K and hTOP2A652T again
conferring lower resistance (interestingly, hTOP2L926F
proved highly EtopR, but only provided low-level resistance
to vosaroxin) (Figure 2B). While performing the screen
with hTOP2, attempts were made to identify mutations
that might provide susceptibility to ciprofloxacin. A total
of 2500 colonies were screened by negative selection, but no
ciprofloxacin-sensitive isolates were detected.
Since yTOP2 proved susceptible to ciprofloxacin (Fig-
ure 2A), this topoisomerase was further used to screen for
mutant alleles that might discriminate between different
quinolone poisons; i.e. changes that conferred resistance
to ciprofloxacin, vosaroxin or both. Approximately 28 000
transformants complemented for growth at non-permissive
temperature by a pool of mutant yTOP2 expression plas-
mids were plated out on 500 M ciprofloxacin to select
for functional mutant alleles that conferred drug-resistance.
Transferring these colonies onto fresh plates containing
500 M ciprofloxacin confirmed 363 colonies (∼1.30%) as
CipR. When tested for vosaroxin resistance by transferring
colonies onto plates containing 100 M vosaroxin, 45%
had a ciprofloxacin- and vosaroxin-resistant (CipRVosR)
phenotype, whereas the remaining 55% were ciprofloxacin-
resistant but vosaroxin-sensitive (CipRVosS). In a screen se-
lecting for initial vosaroxin resistance, no colonies were re-
covered that could be identified as CipSVosR. When as-
sessed for etoposide resistance, the CipRVosS mutations
fell into two classes (Figure 3A). The first, which con-
tained two different single point mutants (yTOP2V197M and
yTOP2A484V) and a triple mutant (yTOP2M975I/V976I/T1365I),
conferred ciprofloxacin resistance but had no impact on
etoposide sensitivity (Figure 3A). The second contained
only single yTOP2 mutations (S9F, L148F, A484T and
S729N), and manifest a 100- to 10 000- fold increase in
etoposide resistance. All examined mutations that gener-
ated vosaroxin resistance also conferred ciprofloxacin and
etoposide resistance (Figure 3B). Interestingly, some of the
observed mutations were quite selective in their resistance
behavior. For example, the yTOP2A484V change produced
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Figure 3. Mutant yTOP2 alleles can discriminate between topoisomerase poisons. (A) Viable counts of JN394t2–4 complemented with yTOP2 CipRVosS
mutants. (B) Viable counts of JN394t2–4 complemented with yTOP2 CipRVosR mutants. Numbers in parentheses indicate the rank position of the mutation
if it falls within the top 100 hits from the later NGS screen.
a CipR phenotype, whereas a threonine change at this po-
sition was CipREtopR and a glycine change was triply
CipRVosREtopR (Figure 3B). Our screen therefore led to
the selection, identification and validation of both broadly
resistant and drug-selective yTOP2 mutant alleles.
Resistance mutations to topoisomerase poisons do not local-
ize to any one enzyme region
Having obtained proof-of-principle for our selection strat-
egy (Figures 2B and 3), we developed an NGS-based ap-
proach to screen larger mutant pools (Supplementary Fig-
ure S2). Through NGS it was possible to obtain sequence
information more rapidly and for a far greater number
of colonies than would have been practically feasible us-
ing Sanger methods applied to single colonies from clas-
sic genetic-screens. Colony collections comprising 374 VosR
hTOP2 mutants, 545 CipRVosS yTOP2 mutants and 209
CipRVosR yTOP2 mutants were first isolated by manual
picking.Mutant plasmids were then prepared in pools, used
to generate PCR-amplified libraries of topoisomerase genes
and sequenced by NGS. Mutations were ranked according
to the number of reads containing the nucleotide change.
The top 100 mutations were selected as a cut-off and were
taken from totals of 13 781 VosR hTOP2mutations, 12 873
CipRVosS yTOP2 mutations and 12 871 CipRVosR yTOP2
mutations. Each set of 100 mutants comprised 46, 36 and
46% of the total number of reads for each phenotypic class,
respectively. This conservative cut-off ensured that we ex-
amined only those hits which occurred relatively frequently
(>2400 reads) in comparison to a long tail of mutants with
low numbers of reads (Supplementary Figure S3).
Surprisingly, the top 100 mutations found from each
NGS screen turned out to be broadly distributed through-
out the topoisomerase coding sequence (Figure 4A; Sup-
plementary Figure S4 and Table S1). For hTOP2, 46 of
the observed mutations mapped to the DNA-binding do-
main andwinged-helix domain (WHD), 19 to the TOPRIM
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Figure 4. The top 100 hits from the NGS screens for poison-resistant topoisomerase II alleles are dispersed throughout the topoisomerase structure. (A)
Linear schematic of hTOP2 (upper) and yTOP2 (lower). Each domain is labeled and described by bordering residue numbers. In the case of the Greek key,
WHD and dimerization domains, these are embedded within larger regions. Numbers in parentheses indicate the number of mutations from the top 100
hits found within each domain, not including those found in an embedded domain (where applicable). With yTOP2, the first number in parentheses refers
to the hits from the CipRVosS screen and the second number relates to the CipRVosR screen. (B) Overview of yTOP2, with one monomer colored as per
(A) and the second monomer shown in transparent gray. DNA backbone and bases are shown in orange and wheat, respectively. Residues identified within
the top 100 hits of the CipRVosS screen are indicated by brown alpha-carbon spheres, residues identified within the top 100 hits of the CipRVosR screen
are shown as purple alpha-carbon spheres and residues that overlap both screens are shown as blue alpha-carbon spheres. A 90◦ rotation of yTOP2 is also
shown. (C) Tilted view of the boxed region in (B), with the ATPase domain and the partner protomer/DNA fragments removed for ease of visualization.
Residues identified within the top 100 hits of the yTOP2 screens and tested in Figures 3 and 5 are shown and colored as in (B). Mutations that were
additionally EtopR are marked with an asterisk. Boxed mutations are those used for later in vitro testing. (B and C) were adapted from PDB entry: 4GFH.
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and Greek-key domains and a small number to the ATPase
and tower domains (7 and 8, respectively). An additional
five hits were found in the coiled-coil and primary dimeriza-
tion domain, and 10 more in the unstructured C-terminal
domain (CTD). The distribution for the yTOP2 mutants
was similar, except that a slightly smaller number of sub-
stitutions fell within the DNA-binding domain and WHD
(40 for CipRVosS and 30 for CipRVosR) and a greater num-
ber mapped to the ATPase region (22 for CipRVosS and 17
for CipRVosR) (Figure 4A). The structures of yTOP2 (29)
and hTOP2 (23,24) were used to map the overall distri-
bution of the top 100 hits (Figure 4B and Supplementary
Figure S5). Taking into account read-frequency, functional
regions, position of known drug-binding residues and se-
quence conservation (Figure 4C and Supplementary Fig-
ure S6), 23 mutants were chosen in order to confirm the
phenotypes of hits from our NGS screen. The selected mu-
tations were introduced by site-directed mutagenesis into
the parental hTOP2 and yTOP2 complementation plas-
mids, which were then used to transform JN394t2–4 for test-
ing against the three topoisomerase poisons (Figure 5). All
mutations identified from the hTOP2 VosR screen were
doubly VosREtopR (with hTOP2A748V proving to be only
weakly EtopR) (Figure 5A), even when the changes fell
far outside the known binding site for etoposide (such as
hTOP2L531F). From the yTOP2 CipRVosS screen, muta-
tions fell in two groups, with the single A457T, G737D,
A725E or E430K changes each conferring CipREtopR, and
the others showing only CipR (Figure 5B). The mutations
within these two groups also appeared to cluster indepen-
dently of their ranking within the NGS screen (Figure 5B).
For the CipRVosR screen, nearly all mutations tested led
to resistance against all three poisons; the one exception
was yTOP2A830V, which despite ranking fifth in total num-
ber of reads for the screen, remained sensitive to all three
drugs (this complete lack of resistance suggests that A830V
may work in conjunction with one or more secondary mu-
tations within yTOP2) (Figure 5C). Nevertheless, 22 of the
23 tested mutations recapitulated the phenotype expected
from the NGS screen, validating the practical utility of this
approach for the high-throughput identification of drug-
resistance mutations.
Assessing the biochemical effects of vosaroxin, ciprofloxacin
and etoposide on wild-type yTOP2 and hTOP2 versus se-
lect resistance mutants
Before assessing whether the drug-resistant mutants iden-
tified by our genetic screens also impart resistance in vitro,
we first examined the response of purified full-length WT
hTOP2 and yTOP2 enzymes to different poisons, along-
side full-length hTOP2 as an additional comparison. WT
enzymes were tested for their ability to relax negatively su-
percoiled plasmid DNA in the presence of different drug
concentrations, using native agarose gel electrophoresis
with and without ethidium bromide to aid the visualization
of nicked and linear products (Figure 6). With all three en-
zymes, vosaroxin induced a low level of DNA nicking and
double stranded cleavage and also initially appeared to in-
hibit supercoil relaxation as well (Figure 6A–E). In agree-
ment with a recent report (56), ciprofloxacin did not ap-
pear to stimulate DNA cleavage or nicking by hTOP2 and
hTOP2 (Figure 6A, B, F and G), but at the highest con-
centration tested (500 M), did begin to inhibit DNA su-
percoil relaxation (Figure 6A and B). These findings in-
dicate that whereas JN394t2–4 cells can still grow in the
presence of ciprofloxacin when complemented by hTOP2
and hTOP2 (Figure 2A), sustained elevated levels of
ciprofloxacin can nonetheless interfere with DNA super-
coil relaxation by these enzymes. In contrast, ciprofloxacin
had no discernible impact on supercoil relaxation but read-
ily promoted DNA cleavage and nicking by yTOP2 (Figure
6C, F and G), consistent both with its ability to kill yeast
cells in the complementation screen (Figure 2A) and prior
biochemical studies of the purified protein (57,58). Etopo-
side induced an (expected) increase in the amount of linear
products produced by all enzymes, albeit more weakly for
hTOP2 and hTOP2 as compared to yTOP2 (Figure 6A–
C and H). Etoposide also induced low levels of nicking in
hTOP2 and hTOP2, but very little, if any, nicking with
yTOP2 (Figure 6C and I).
Although vosaroxin induced a low level of DNA cleav-
age with all three enzymes tested (Figure 6A–D), this
agent has also been proposed to act as a general inhibitor
of topoisomerase II-dependent DNA supercoil relaxation
(36). Vosaroxin readily intercalates into DNA (36), an ac-
tivity that can be seen upon incubating nicked DNA with
the drug and sealing the nick with ligase (Supplementary
Figure S7A). By itself, vosaroxin has no apparent effect
on supercoiled or relaxed plasmid DNA in the absence
of topoisomerase (Supplementary Figure S7B). Based on
these properties, we hypothesized that the apparent ‘inhi-
bition’ of topoisomerase II-dependent supercoil relaxation
seen with vosaroxin (Figure 6A–C) might be misleading,
and actually reflects the outcome of active strand passage
events by topoisomerase II that trap changes in DNA twist
arising from the intercalation of vosaroxin into DNA. To
test this idea, we pre-incubated WT and mutant hTOP2
or yTOP2 enzymes with pre-relaxed plasmid DNA in the
presence of varying amounts of the drug (Figure 7A and B,
left third of the gels). In solvent-only control lanes, the pre-
relaxed substrate is unaffected by the enzymes. However,
as vosaroxin concentrations are increased, the plasmid be-
comes supercoiled. Comparative reactions run on agarose
gels in the presence and absence of ethidium bromide at
higher vosaroxin concentrations lead to the production of a
plasmid species that co-migrates with the supercoiled con-
trol plasmid. These data argue against the possibility that
vosaroxin acts as a catalytic inhibitor of supercoil relaxation
by type II topoisomerases (36), and instead strongly sup-
port the conclusion that vosaroxin’s toxicity derives from
its action as a topoisomerase II poison and/or as a DNA
intercalating agent.
Having established a baseline for drug action on topoi-
somerase II function in vitro, we next examined a pair
of drug-resistance mutants for hTOP2 and yTOP2. The
hTOP2P716H and hTOP2L926F mutants were both VosR
in our genetic screens, with hTOP2P716H being strongly-
resistant and hTOP2L926F being weakly resistant (Fig-
ure 2B). By comparison, for the yTOP2 mutants, the
G832S mutation is CipRVosR (Figure 5C), whereas the
A484V mutation is CipRVosS (Figure 3A). The vosaroxin-
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Figure 5. NGS screen-identified mutations were confirmed by phenotypic testing. (A) Viable counts of JN394t2–4 complemented with hTOP2 VosR mu-
tants. (B) Viable counts of JN394t2–4 complemented with yTOP2 CipRVosS mutants. (C) Viable counts of JN394t2–4 complemented with yTOP2 CipRVosR
mutants. Numbers in parentheses indicate the rank position of the mutation within the top 100 hits of the NGS screen.
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Figure 6. Effects of antibacterial and anticancer topoisomerase poisons on eukaryotic topoisomerases. Relaxation of negatively supercoiled plasmid DNA
by WT full-length (A) hTOP2, (B) hTOP2 and (C) yTOP2, titrated against vosaroxin, ciprofloxacin and etoposide. The positions of linear (L), nicked
(N), relaxed (R) and supercoiled (SC) plasmids DNAs are indicated. Images are representative of triplicate comparative reactions, using agarose gels
with and without 0.5 g.ml−1 ethidium bromide (EtBr). (D–I) DNA linearization and nicking by WT full-length (FL) enzymes as induced by (D and E)
vosaroxin, (F and G) ciprofloxacin and (H and I) etoposide, quantified by densitometry. Error bars represent the standard deviation of triplicate data.
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Figure 7. Protection from vosaroxin-induced double-strand breaks by re-
sistance mutations. (A) Comparison of WT full-length (FL) hTOP2 su-
percoiling activity on relaxed plasmid DNA with that of VosR mutants
P716H and L926F, titrated against vosaroxin. (B) Comparison ofWT full-
length (FL) yTOP2 supercoiling activity on relaxed plasmid DNA with
that of CipRVosR mutant G832S and CipRVosS mutant A484V, titrated
against vosaroxin. (C) Resistance mutations reduce the levels of drug-
induced linearization, as quantified by densitometry. Error bars represent
the standard deviation of triplicate data.
free supercoil relaxation activity of these selected topoi-
somerase II mutants was tested and compared to the
respective WT enzyme (Supplementary Figure S8). The
hTOP2P716H construct had no clear difference in activ-
ity, whereas hTOP2L926F had reduced supercoil relaxation
activity compared to hTOP2 WT (Supplementary Fig-
ure S8A). yTOP2A484V was comparable to yTOP2 WT,
while yTOP2G832S had slightly faster activity (Supplemen-
tary Figure S8B). The impact of vosaroxin on DNA cleav-
A
B
Figure 8. Protection from ciprofloxacin- and etoposide-induced double-
strand breaks by resistance mutations. (A) Comparison of full-length (FL)
WT andmutant yTOP2 plasmid supercoil relaxation activity on negatively
supercoiled plasmid substrate, titrated against ciprofloxacin and etoposide.
The positions of linear (L), nicked (N), relaxed (R) and supercoiled (SC)
plasmids DNAs are indicated. Images are representative of triplicate com-
parative reactions, using agarose gels with and without 0.5 g.ml−1 ethid-
ium bromide (EtBr). (B) Resistance mutations reduce the levels of drug-
induced linearization, as quantified by densitometry. Error bars represent
the standard deviation of triplicate data.
age byWT and these mutant topoisomerase constructs was
then compared in the presence of pre-relaxed plasmidDNA
(Figure 7). In accord with the screening data, vosaroxin-
induced DNA cleavage was reduced to a greater extent
for hTOP2P716H than for hTOP2L926F, and both were
more resistant to the drug than native hTOP2 (Figure 7A
and C). Compared to yTOP2WT, vosaroxin-induced DNA
cleavage was also reduced for the CipRVosR yeast topoiso-
merase II mutant, yTOP2G832S, but less so for the CipRVosS
mutant yTOP2A484V (Figure 7B and C).
Next, the yTOP2 mutants were tested for their sensitivity
to ciprofloxacin and etoposide during supercoil relaxation
(Figure 8). As expected, yTOP2G832S (which is triply resis-
tant to all three drugs tested) formed fewer linear products
than WT yTOP2 with either 10 or 100 M ciprofloxacin,
or with 10 M etoposide (Figure 8). Nevertheless, at the
higher (100 M) etoposide dose, drug-induced lineariza-
tion was similar between yTOP2WT and yTOP2G832S (Fig-
ure 8). Curiously, the yTOP2A484V mutant (which displayed
a CipRVosSEtopS phenotype on plates) appeared modestly
resistant to both ciprofloxacin and etoposide at lower con-
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centration (Figure 8). Collectively, these experiments bio-
chemically confirm that NGS screening approaches are ca-
pable of identifying new drug-resistant mutant hTOP2
and yTOP2 alleles. These findings also show that resistance
to these agents largely manifests as a reduction in cleavage
complex formation and that mutations outside the known
binding locus for type II topoisomerase poisons can have a
significant impact on drug sensitivity without significantly
compromising enzyme activity in vitro.
The nucleolytic cores of human type II topoisomerases are
susceptible to poisoning by etoposide
Type IIA topoisomerase poisons bind deep within the en-
zymes’ conserved nucleolytic core, near the dyad of the
dimer (Figure 1) (25–28,59). Because the drug-resistance
mutations we isolated frequently arose outside of the prin-
ciple drug-binding locus, we were curious as to how the
nucleolytic region alone might respond to poisons. To ad-
dress this question, the DNA binding and cleavage cores of
hTOP2, hTOP2 and yTOP2 (all of which lack the asso-
ciated ATPase and unstructured C-terminal domains) were
purified and assayed against vosaroxin, ciprofloxacin and
etoposide (Figure 9). Etoposide induced plasmid lineariza-
tion by all three core enzymes in a clear, dose-dependent
manner. When testing the full-length enzymes, there was
greater etoposide-induced linearization with yTOP2 full-
length than with the two full-length human topoisomerases
(Figure 6F). With the core enzymes, however, the effects
of etoposide inverted, showing greatest stimulation of lin-
earization for the hTOP2 core, then the hTOP2 core, fol-
lowed by the yTOP2 core (Figure 9D). Curiously, etopo-
side also greatly increased the propensity of the hTOP2
core to nick DNA but had little such effect on the hTOP2
and yTOP2 cores (Figure 9E). By comparison, whereas
vosaroxin induced cleavage by all three full-length enzymes
(Figure 6A–D), only the hTOP2 core generated linear
DNA products in the presence of vosaroxin, and even then
at very low levels (Figure 9A–C) (as previously observed
(36), vosaroxin-induced cleavage peaked at lower drug con-
centrations). Finally, as for the full-length enzymes (Figure
6A and B), no significant ciprofloxacin-induced lineariza-
tion was observed with either the hTOP2 or hTOP2 core
enzymes (Figure 9A and B), and the ciprofloxacin-induced
linearization caused by yTOP2 full-length enzyme (Figure
6C)was reducedwith yTOP2 core enzyme (Figure 9C). Col-
lectively, these data show that the core catalytic region of
human and yeast type II topoisomerases can be poisoned
but that the presence of the ATPase domains in the full-
length enzymes modulates drug-susceptibility of these core
regions.
DISCUSSION
Type IIA topoisomerases catalyze essential DNA unlink-
ing events that can be corrupted by cytotoxic agents of clin-
ical value. We have applied a large-scale mutagenesis and
NGS analysis approach to better understand how eukary-
otic type IIA topoisomerases discriminate between different
classes of type IIA topoisomerase poisons. As a result, we
accessed a global overview of residues frequently involved in
drug discrimination that could be validated biochemically.
In doing so, we also clarified the activity of vosaroxin and
discovered that the susceptibility of the eukaryotic type IIA
topoisomerase cleavage/re-ligation core domain to poisons
is modulated by its ATPase domains.
Type II topoisomerases can escape poisoning through many
routes
Our initial complementation studies built upon previ-
ous work with the temperature-sensitive yeast strain
JN394t2–4 (41–43,45,60–64). All three topoisomerases
tested here––budding yeast TOP2 and human TOP2 and
TOP2––were sensitive to vosaroxin and etoposide (Figure
2A). Interestingly, yTOP2 also proved to be sensitive to
ciprofloxacin (Figure 2A). This finding is in accord with
prior biochemical studies that to our minds have been
overlooked in the field (57,58), and suggest that it may be
possible to repurpose antibacterial fluoroquinolones as
inhibitors of fungal diseases. In this regard, ciprofloxacin
acts synergistically with non-fluoroquinolone antifun-
gals (65,66), but more potent fluoroquinolones, such as
moxifloxacin, have yet to be assessed.
To attempt to more broadly define the potential resis-
tance landscape to type II topoisomerase poisons, we con-
ducted a large screen for drug-resistant topoisomerase II
alleles using an NGS approach. The results of the NGS
screen were corroborated by multiple factors including: (i)
their overlap with hits obtained from our small-scale tradi-
tional genetic screen (Figures 2 and 3) and a number of mu-
tations identified in previously publishedwork (Supplemen-
tary Table S1) (42,45,63,64), and (ii) the validation of NGS-
identified mutant phenotypes in vivo (Figure 5) and in vitro
(Figures 7 and 8). This NGS screening methodology dra-
matically increases both the final total number of mutants
that can be found in a screen and the speed at which they can
be identified.We envision thatNGS screens could be further
improved using a higher number of transformants and addi-
tional mutagenesis strategies beyond hydroxylamine treat-
ment (which favors GC→AT transitions in DNA (67)). As
NGS platforms continue to develop, long-read sequencing,
such as SingleMoleculeReal-Time Sequencing (Pacific Bio-
sciences) or nanopore sequencing (Oxford Nanopore Tech-
nologies), could also be used to capture drug-resistant vari-
ants arising from more than one mutation in the topoiso-
merase gene.
Our NGS screens identified many mutations at widely-
differing loci that conferred similar drug resistance pheno-
types. We also observed multiple changes at a single locus,
and changes within and outside the known quinolone- and
epipodophyllotoxin-binding sites, that can give rise to selec-
tive resistance profiles (e.g. the A484T, A484V and A484G
alterations in yTOP2) (Figure 3). Quinolone-resistance
mutations have previously been identified far from drug-
binding sites (68) (Supplementary Table S1). The emergence
of resistance mutations throughout the entirety of eukary-
otic topoisomerase II (Figure 4A) demonstrates that the
prospective means for avoiding inhibition by type II topoi-
somerase poisons are broad and complex. This behavior dif-
fers from the typical drug-resistance outcomes that more
specifically target residues near the site of drug action, such
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Figure 9. Topoisomerase ATPase domains modulate the impact of topoisomerase poisons. Activity of core (A) hTOP2, (B) hTOP2 and (C) yTOP2
enzymes on negatively supercoiled plasmid DNA as titrated against vosaroxin, ciprofloxacin and etoposide. The positions of linear (L), nicked (N), relaxed
(R) and supercoiled (SC) plasmids DNAs are indicated. Images are representative of triplicate comparative reactions, using agarose gels without ethidium
bromide (EtBr). Etoposide-induced linearization (D) and nicking (E) by core enzymes, as quantified by densitometry. Error bars represent the standard
deviation of triplicate data.
as with -lactamases (69). Although mutations mapping to
the nucleolytic core are found throughout the region, a de-
gree of clustering was evident around the drug-binding re-
gions for quinolones (27,28,70) and etoposide (25) (Figure
4C and Supplementary Figure S6B). A second cluster of
mutations was also seen in a flexible loop region (residues
A830-I841 in yTOP2) bearing a conserved isoleucine, I833,
which intercalates into and bends DNA (71). Although
changes to this isoleucine were not found within the top
100 hits of any of our screens (and would not be expected
to, as the integrity of this position is needed for type IIA
topoisomerase activity (72)), mutations that map to this
loop include yTOP2G832S, the top CipRVosR hit, which is
adjacent to the intercalative isoleucine. A surprisingly high
number ofmutations were also foundwithin theN-terminal
ATPase domains, such as yTOP2V197M (CipRVosS) (Figure
3A), which would be expected to alter ATP turnover by
modifying the ATP-binding pocket. This observation sug-
gests that a mechanistic link exists between ATP turnover
and drug sensitivity, although the impact of this linkage dif-
fers significantly between topoisomerase homologs (as seen
by the lower levels of mutations found in the ATPase do-
main of hTOP2 in comparison to yTOP2, Figure 4A). Al-
together, the observed patterns of mutations in the nucle-
olytic core and ATPase domains suggest that binding and
bending of the cleaved-DNA segment, which is coupled to
the stimulation of ATP hydrolysis and strand passage (72),
can have a profound effect on the potency and selectiv-
ity of type II topoisomerase poisons. Lastly, multiple drug-
resistance mutations were identified in the unstructured C-
terminal domains (Figure 4A). How these mutations would
confer resistance is not immediately clear, but could impact
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catalytic activity, nuclear localization or both. Drug selec-
tivity between topoisomerases therefore appears to be dic-
tated by factors beyond just the favorability of the com-
pound binding to the active site. Selectivity is instead likely
to also include internal aspects such as conformational dy-
namics, overall catalytic rate and target DNA sequence and
structure, along with extrinsic factors such as binding part-
ners, cellular localization and local concentration. Focused
studies involving different types of assays and different pan-
els of mutants than those assessed here will be needed to
more finely tease apart these couplings.
In some instances, our in vitro tested mutants had altered
supercoil relaxation activity (Supplementary Figure S8). In
particular, a reduction of topoisomerase activity can confer
drug resistance (73), as was the case for hTOP2L926F (Sup-
plementary Figure S8A). By contrast, both hTOP2P716H
and yTOP2A484V did not have altered relaxation activity
compared toWT, whereas yTOP2G832S had increased activ-
ity (Supplementary Figure S8). This result neatly demon-
strates that there are multiple routes by which drug resis-
tance can arise which may or may not directly impact cat-
alytic function.
Quinolone activity against eukaryotic type IIA topoiso-
merases can be modulated
Fluoroquinolones constitute one of the most popular treat-
ments for bacterial infections and form the basis of a multi-
billion dollar-per-year industry (31). Part of the success
of fluoroquinolone-class drugs derives from their ability
to preferentially act against prokaryotic type IIA topoi-
somerases such as gyrase and topoisomerase IV across a
broad spectrum of bacteria (74), and because they are gen-
erally well-tolerated (75). Understanding the mechanism of
fluoroquinolone specificity is important, not only as there
is much debate over their side-effects (76), but also be-
cause quinolone variants that act against eukaryotic topoi-
somerase IIs are prospective anti-fungal and anti-cancer
agents. Vosaroxin is one such quinolone variant known to
have fewer toxic side-effects than other poisons, such as re-
duced reactive oxygen species production (36). Initial stud-
ies on vosaroxin demonstrated its activity against eukary-
otic topoisomerase IIs (36,77), suggesting a potential use in
treating AML (78). Thus far, vosaroxin has passed through
phase 2 clinical trials (79) and has shown cautiously pos-
itive Phase 3 trial results in patients with relapsed or re-
fractory AML (37). Vosaroxin is thought to have two ac-
tivities against topoisomerase II: poisoning, which leads to
DNA breaks, and the general inhibition of DNA supercoil
relaxation (36). An apparent ability of vosaroxin to block
negative supercoil relaxation was seen for all three enzymes
tested (Figure 6); however, upon further investigation, we
discovered that the retention of supercoiled substrate ob-
served at increasing vosaroxin concentrations actually de-
rived from topoisomerase II acting upon DNA supercoils
formed by the intercalation of the drug into DNA (Supple-
mentary Figure S7). Mutations that gave rise to vosaroxin
resistance reduced the levels of DNA cleavage induced by
the drug, but had no effect on this supercoiling activity (Fig-
ures 7 and 8). These data indicate that the cytotoxic behav-
ior of vosaroxin arises primarily from its ability to poison
topoisomerase II and stimulate dsDNA break formation,
and not from a general inhibition of enzyme activity, as
previously highlighted for other poisons (41,80). This sep-
aration should be considered when studying purported in-
hibitors of type II topoisomerases that are also DNA inter-
calating agents.
As might have been expected, the nucleolytic cores of
the tested topoisomerase II enzymes remained suscepti-
ble to etoposide poisoning (Figure 9). This response man-
ifested as dose-dependent linearization by all three core
enzymes, but also as significant nicking by the hTOP2
core (Figure 9E). In addition, the sensitivity profiles of
the core enzymes frequently differed from that of their
full-length counterparts. For instance, yTOP2 displayed re-
duced ciprofloxacin-susceptibility when liberated from its
ATPase elements and unstructured C-terminal tail (Figure
9C) compared to the full-length enzyme (Figure 6C). Sec-
ond, although all full-length topoisomerase IIs proved sus-
ceptible to vosaroxin poisoning (Figure 6A–D), only the
nucleolytic core of hTOP2 proved sensitive to vosaroxin
on its own (Figure 9B). These observations not only cor-
roborate the NGS data showing that the ability of poisons
to act against type II topoisomerases can be modulated by
regions outside of the principle drug binding locus, they
also demonstrate that ATPase status, which controls DNA
cleavage behavior (29,81), can be linked to drug efficacy and
specificity. Interestingly, our data additionally highlight that
the cores of hTOP2 and hTOP2 respond significantly dif-
ferently to poisoning. Gaining a better understanding of the
principles defining these behavioral differences will aid in
developing isoform-specific inhibitors as cancer therapeu-
tics with reduced off-target toxicity.
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